The global adrenocortical carcinoma treatment market is expected to grow steadily over the forecast period. It is estimated that the global adrenocortical carcinoma treatment market is expected to register a CAGR ~ 2.6 % with an anticipated market value of 678 million during the forecast period from 2018 to 2023.
Adrenocortical carcinoma is cancer that arises from the adrenal cortex, which is the outer layer of the adrenal gland. It is rare and aggressive in form, and the management requires a multidisciplinary approach. Numerous factors such as an increase in prevalence rates of rare cancers and the increased focus of companies on the treatment of adrenocortical carcinomas are expected to drive the growth of the market. Thus, there is an increase in the number of drugs in clinical trials for specific chemotherapeutics. According to the Journal of Clinical Endocrinology & Metabolism, the incidence of adrenocortical carcinoma ranges between 40-50 years, whereas women are 55–60% more likely to get affected with a ratio of 1.5:1. In April 2015, ArQule, Inc. announced ARQ 087 is currently in a Phase 2 trial in patients with Intrahepatic Cholangiocarcinoma (ICC) with FGFR2 fusions and a Phase 1b trial in adrenocortical tumors and tumors with FGFR translocations, amplification, and mutations. ARQ 087 is a potent FGFR (Fibroblast Growth Factor Receptor) inhibitor.
Segmentation
The global adrenocortical carcinoma treatment market has been segmented into type, therapy, and end-user.
The market, on the basis of type, has been segmented into localized adrenocortical carcinoma and metastatic adrenocortical carcinoma.
The localized adrenocortical carcinoma segment is estimated to hold the largest share as it is the most common type with a high occurrence rate. The metastatic adrenocortical carcinoma segment is projected to be the fastest growing owing to increased occurrence rate.
The market, by therapy, has been segmented into surgery, chemotherapy, targeted therapy, radiation therapy, adjuvant therapy, and others.
The market, based on surgery, has been further segmented into laparoscopic surgery and open surgery.
The market, on the basis of radiation therapy, has been sub-segmented into external beam radiation therapy and brachytherapy.
The market, on the basis of end-user, has been segmented into hospitals and clinics, ambulatory surgical centers, and cancer research institutes.
Key players
Arqule, Pfizer Ltd., EnGeneIC Ltd, Exelixis, Inc., Millendo Therapeutics, Inc., Merck & Co., Orphagen Pharmaceuticals, Inc., HRA Pharma, Bristol-Myers Squibb Company, General Electric Company, WG Critical Care, LLC, Mylan N.V., Fresenius Kabi AG, Sinovision Technologies (Beijing) CO., Ltd.
Hitachi, Ltd., NeuroLogica Corp., and Digirad Corporation are some of the key players in the global adrenocortical carcinoma treatment market.
Global Adrenocortical Carcinoma Treatment Market, by Type
- Localized Adrenocortical Carcinoma
- Metastatic Adrenocortical Carcinoma
Global Adrenocortical Carcinoma Treatment Market, by Therapy
- Surgery
- Laparoscopic surgery
- Open surgery
- Chemotherapy
- Targeted Therapy
- Radiation Therapy
- External beam radiation therapy
- Brachytherapy
- Adjuvant Therapy
- Others
Global Adrenocortical Carcinoma Treatment Market, by End-User
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Cancer Research Institutes
Request Customization
Get a Sample
Get a Sample
Request Customization